Thromb Haemost 2007; 98(02): 296-303
DOI: 10.1160/TH07-02-0140
Theme Issue Article
Schattauer GmbH

CREB binding to the hypoxia-inducible factor-1 responsive elements in the plasminogen activator inhibitor-1 promoter mediates the glucagon effect

Elitsa Y. Dimova
1   Department Chemistry/Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany
,
Malgorzata M. Jakubowska
1   Department Chemistry/Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany
,
Thomas Kietzmann
1   Department Chemistry/Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany
› Institutsangaben
Financial support: This study was supported by the grants from Fonds der Chemischen Industrie and Deutsche Krebshilfe 106929.
Weitere Informationen

Publikationsverlauf

Received 23. Februar 2007

Accepted after revision 21. April 2007

Publikationsdatum:
28. November 2017 (online)

Summary

Plasminogen activator inhibitor-1 (PAI-1) controls the regulation of the fibrinolytic system in blood by inhibiting both urokinase-type and tissue-type plasminogen activators. Enhanced levels of PAI-1 are related to pathological conditions associated with hypoxia or hyperinsulinemia. In this study, we investigated the regulation of PAI-1 expression by glucagon and the cAMP/ PKA/CREB signalling pathway in the liver. Stimulation of the cAMP/PKA/CREB signalling cascade by starvation in vivo or glucagon in vitro induced PAI-1 gene expression in liver. Furthermore, this response was associated with enhanced phosphorylation of CREB. By using EMSAs we found that three promoter elements, the HRE2, E-box 4 and E-box 5, were able to bind CREB but only the HRE2 and E5 appeared to be functionally active. Reporter gene assays confirmed that cAMP induced PAI-1 gene transcription via the same element in both human and rat promoters. Interestingly, although the HRE2 was involved, the glucagon/cAMP pathway had no influence on hypoxia-inducible factor-1 (HIF-1) mRNA and protein levels. Thus, CREB binding to the HIF-1 responsive elements in PAI-1 promoter mediates the glucagon effect in the liver.

 
  • References

  • 1 Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143: 949-958.
  • 2 Erickson LA, Schleef RR, Ny T. et al. The fibrinolytic system of thevascular wall. Clin Haematol 1985; 14: 513-530.
  • 3 Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266: 9419-9427.
  • 4 Busso N, Nicodeme E, Chesne C. et al. Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology 1994; 20: 186-190.
  • 5 Mimuro J, Loskutoff DJ.. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264: 936-939.
  • 6 Dellas C, Loskutoff DJ.. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
  • 7 Fink T, Kazlauskas A, Poellinger L. et al. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 2002; 99: 2077-2083.
  • 8 Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via ahypoxia response element binding the hypoxia inducible factor-1 in rat hepatocytes. Blood 1999; 94: 4177-4185.
  • 9 Dimova EY, Moller U, Herzig S. et al. Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells. Thromb Haemost 2005; 93: 1176-1184.
  • 10 Juhan VI, Roul C, Alessi MC. et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373.
  • 11 Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42: 1-7.
  • 12 Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-F220.
  • 13 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
  • 14 Jelinek LJ, Lok S, Rosenberg GB. et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 1993; 259: 1614-1616.
  • 15 Mayo KE, Miller LJ, Bataille D. et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167-194.
  • 16 Lee CQ, Yun YD, Hoeffler JP. et al. Cyclic-AMP-responsive transcriptional activation of CREB-327 involves interdependent phosphorylated subdomains. EMBO J 1990; 9: 4455-4465.
  • 17 Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989; 59: 675-680.
  • 18 Montminy M, Koo SH, Zhang X. The CREB family: key regulators of hepatic metabolism. Ann Endocrinol (Paris) 2004; 65: 73-75.
  • 19 Immenschuh S, Hinke V, Ohlmann A. et al. Transcriptional activation of the haem oxygenase-1 gene by cGMP via a cAMP response element/activator protein-1 element in primary cultures of rat hepatocytes. Biochem J 1998; 334: 141-146.
  • 20 Kietzmann T, Roth U, Freimann S. et al. Arterial oxygen partial pressures reduce the insulin-dependent induction of the perivenously located glucokinase in rat hepatocyte cultures: mimicry of arterial oxygen pressures by H2O2. Biochem J 1997; 321: 17-20.
  • 21 Kietzmann T, Samoylenko A, Roth U. et al. Hypoxia-inducible factor-1 and hypoxia response elements mediate the mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 2003; 101: 907-914.
  • 22 Dimova EY, Kietzmann T. MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. Ann NY Acad Sci 2006; 1090: 355-367.
  • 23 Heaton JH, Nebes VL, O’Dell LG. et al. Glucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes. Mol Endocrinol 1989; 3: 185-192.
  • 24 Uno S, Nakamura M, Ohomagari Y. et al. Regulation of tissue-type plasminogen activator (tPA) and type-1 plasminogen activator inhibitor (PAI-1) gene expression in rat hepatocytes in primary culture. J Biochem Tokyo 1998; 123: 806-812.
  • 25 Heaton JH, Gelehrter TD. Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells. Mol Endocrinol 1990; 4: 171-178.
  • 26 Heaton JH, Tillmann BM, Leff NS. et al. Cyclic nucleotide regulation of type-1 plasminogen activator-in hibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences. J Biol Chem 1998; 273: 14261-14268.
  • 27 Tillmann-Bogush M, Heaton JH, Gelehrter TD. Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence. J Biol Chem 1999; 274: 1172-1179.
  • 28 Heaton JH, Dlakic WM, Dlakic M. et al. Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA. J Biol Chem 2001; 276: 3341-3347.
  • 29 Johnson MR, Bruzdzinski CJ, Winograd SS. et al. Regulatory sequences and protein-binding sites involved in the expression of the rat plasminogen activator inhibitor-1 gene. J Biol Chem 1992; 267: 12202-12210.
  • 30 Bruzdzinski CJ, Johnson MR, Goble CA. et al. Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identification of cis-acting regulatory elements. Mol Endocrinol 1993; 7: 1169-1177.
  • 31 Dimova EY, Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen acti-vator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem 2006; 281: 2999-3005.
  • 32 Riccio A, Pedone PV, Lund LR. et al. Transforming growth factor beta 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene. Mol Cell Biol 1992; 12: 1846-1855.
  • 33 Hua X, Liu X, Ansari DO. et al. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 1998; 12: 3084-3095.
  • 34 Dennler S, Itoh S, Vivien D. et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-3100.
  • 35 Allen RR, Qi L, Higgins PJ. Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes. J Cell Physiol 2005; 203: 156-165.
  • 36 Kvietikova I, Wenger RH, Marti HH. et al. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 1995; 23: 4542-4550.
  • 37 Kvietikova I, Wenger RH, Marti HH. et al. The hypoxia-inducible factor-1 DNA recognition site is cAMP-responsive. Kidney Int 1997; 51: 564-566.
  • 38 Beitner-Johnson D, Millhorn DE. Hypoxia induces phosphorylation of the cyclic AMP response element-binding protein by anovel signaling mechanism. J Biol Chem 1998; 273: 19834-19839.
  • 39 Zelzer E, Levy Y, Kahana C. et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBOJ 1998; 17: 5085-5094.
  • 40 Forsythe JA, Jiang BH, Iyer NV. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
  • 41 Amano H, Ando K, Minamida S. et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 2001; 87: 181-188.
  • 42 Claffey KP, Wilkison WO, Spiegelman BM. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992; 267: 16317-16322.
  • 43 Thoresen GH, Sand TE, Refsnes M. et al. Dual effects of glucagon and cyclic AMP on DNA synthesis in cultured rat hepatocytes: stimulatory regulation in early G1 and inhibition shortly before the S phase entry. J Cell Physiol 1990; 144: 523-530.
  • 44 Diehl AM, Yang SQ, Wolfgang D. et al. Differential expression of guanine nucleotide-binding proteins enhances cAMP synthesis in regenerating rat liver. J Clin Invest 1992; 89: 1706-1712.
  • 45 Uno S, Nakamura M, Seki T. et al. Induction of tissue-type plasminogen activator (tPA) and type-1 plasminogen activator inhibitor (PAI-1) as early growth responsesin rat hepatocytes in primary culture. Biochem Biophys Res Commun 1997; 239: 123-128.
  • 46 Yee JA, Yan L, Dominguez JC. et al. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblastlike cells. J Cell Physiol 1993; 157: 528-534.
  • 47 Grant MB, Ellis EA, Caballero S. et al. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy. Exp Eye Res 1996; 63: 233-244.